FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy

Bristol-Myers Squibb said the FDA rejected its new drug application for its hepatitis C treatment in combination with other agents, pending submission of more information requested by the regulator.



from WSJ.com: US Business http://ift.tt/1FrzrY9

via IFTTT